Morgan Stanley Analyst Upgrades Axsome Therapeutics to EqualWeight with Raised Price Target
On June 12, 2023, Vikram Purohit, an analyst at Morgan Stanley, updated his rating on Axsome Therapeutics (NASDAQ:AXSM) to Equal-Weight ...
Tag: AXSM
Global Investment Firm Sei Investments Co. Reduces Stake in Axsome Therapeutics, Inc.
On June 2, 2023, global investment firm Sei Investments Co. announced a reduction in its stake of Axsome Therapeutics, Inc. ...
Blair William & Co. IL reduces stake in Axsome Therapeutics, Inc. as AXSM maintains strong position within pharmaceutical industry
In a recent Form 13F filing with the SEC, Blair William & Co. IL revealed its decision to reduce its ...
Axsome Therapeutics Assigned Moderate Buy Consensus Recommendation by Fifteen Research Firms
May 26, 2023: Axsome Therapeutics, Inc. (NASDAQ:AXSM), the New York-based biopharmaceutical company focused on developing innovative and highly differentiated therapies ...
Axsome Therapeutics Reports Impressive Q1 Revenues Despite Losses
On May 8, 2023, Axsome Therapeutics announced impressive Q1 revenues that exceeded expectations. The biopharmaceutical company reported a revenue of ...
Axsome Therapeutics Exceeds Q1 Financial Expectations with Strong Sales Performance
On May 8, 2023, Axsome Therapeutics (NASDAQ: AXSM) announced their Q1 financial results, which exceeded analyst expectations. The company reported ...
Industry Experts Recommend ‘Moderate Buy’ for Axsome Therapeutics
On May 1, 2023, renowned news outlet 'Bloomberg' reported that &Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been recommended as a "Moderate ...
New York State Common Retirement Fund Increases Stake in Axsome Therapeutics, Signaling Confidence in Biotech Industry’s Future
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapies for the ...
Axsome Therapeutics: Advancing Neurological Treatments Through Innovative Discoveries and Careful Research
Axsome Therapeutics: Experiencing Neurological Advancements Amidst A Tumultuous Earnings Quarter Axsome Therapeutics (NASDAQ:AXSM) has been making waves in the biopharmaceutical ...
Moody Aldrich Partners LLC Cuts Position in Axsome Therapeutics by Over 50% during Q4 2019
In the world of finance, there are few things more captivating than identifying market trends and poring over companies' financial ...